MENU
+Compare
ARCT
Stock ticker: NASDAQ
AS OF
Dec 24 closing price
Price
$16.53
Change
+$0.02 (+0.12%)
Capitalization
447.75M

ARCT Arcturus Therapeutics Holdings Forecast, Technical & Fundamental Analysis

a developer of technology and therapeutics for rare diseases

Industry Biotechnology
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ARCT with price predictions
Dec 24, 2024

ARCT's RSI Oscillator ascends from oversold territory

The RSI Indicator for ARCT moved out of oversold territory on December 20, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In of the 32 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where ARCT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 13, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ARCT turned negative on December 16, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ARCT entered a downward trend on November 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.710) is normal, around the industry mean (18.292). P/E Ratio (0.000) is within average values for comparable stocks, (87.498). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.756). ARCT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (3.125) is also within normal values, averaging (260.038).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ARCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ARCT is expected to report earnings to fall 26.92% to -18 cents per share on March 03

Arcturus Therapeutics Holdings ARCT Stock Earnings Reports
Q4'24
Est.
$-0.19
Q3'24
Beat
by $0.31
Q2'24
Beat
by $0.38
Q1'24
Beat
by $0.06
Q4'23
Beat
by $0.63
The last earnings report on November 07 showed earnings per share of -25 cents, beating the estimate of -56 cents. With 169.66K shares outstanding, the current market capitalization sits at 447.75M.
A.I. Advisor
published General Information

General Information

a developer of technology and therapeutics for rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
10628 Science Center Drive
Phone
+1 858 900-2660
Employees
180
Web
https://www.arcturusrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDSIX23.110.27
+1.18%
Hodges Small Cap Institutional
JSGTX28.520.33
+1.17%
JHancock U.S. Growth R6
FNKCX14.570.16
+1.11%
Frank Value C
FCUDX19.420.16
+0.83%
NYLI PineStone U.S. Equity Class R6
AEYIX8.400.04
+0.48%
American Century Equity Income C

ARCT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with BMEA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+0.12%
BMEA - ARCT
52%
Loosely correlated
-0.50%
AXON - ARCT
49%
Loosely correlated
+1.14%
ABCL - ARCT
48%
Loosely correlated
+1.03%
PGEN - ARCT
45%
Loosely correlated
+5.24%
BEAM - ARCT
44%
Loosely correlated
+0.38%
More